Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) announced it has entered into a Securities Purchase Agreement with certain institutional investors to sell 9,790,000 shares of common stock …
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced receipt from the United States Patent and Trademark Office (“USPTO”) …
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) announced that Acura has entered into a License and Development Agreement with Bayer Healthcare LLC to provide an exclusive worldwide …
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the first …
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), announced that it is initiating development of an immediate-release hydrocodone bitartrate with acetaminophen tablet (“hydrocodone/APAP”) incorporating Acura’s novel LIMITX™ …
Roth Capital analyst Ed Arce reiterated a Buy rating on Acura (NASDAQ:ACUR) with a price target of $1.50, which represents a potential upside …
In a research report issued today, Roth Capital analyst Ed Arce reiterated a Buy rating on Acura (NASDAQ:ACUR) with a $1.50 price target, …
In a research report issued today, Roth Capital analyst Ed Arce maintained a Buy rating on Acura (NASDAQ:ACUR) with a $1.50 price target, following …